Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$12.35 +0.6%	$12.00	$8.04 ▼ $28.05	$334.94M	2.3	434,978 shs	377,342 shs
CMPS COMPASS Pathways	$4.80 +7.1%	$4.06	$2.49 ▼ $8.54	$449.10M	2.25	920,182 shs	3.06 million shs
OLMA Olema Pharmaceuticals	$4.10 +2.2%	$4.66	$2.86 ▼ $16.62	$280.53M	1.99	821,615 shs	644,135 shs
RANI Rani Therapeutics	$0.51 -1.1%	$0.79	$0.46 ▼ $4.37	$29.20M	N/A	817,654 shs	333,178 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	+0.57%	-0.72%	+3.00%	-3.82%	-52.43%
CMPS COMPASS Pathways	+7.14%	+4.58%	+10.34%	+62.16%	-25.35%
OLMA Olema Pharmaceuticals	+2.24%	+0.49%	-14.58%	-0.49%	-65.83%
RANI Rani Therapeutics	-1.15%	-11.30%	-27.43%	-66.13%	-86.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	3.0361 of 5 stars	4.6	0.0	2.7	2.5	0.6
CMPS COMPASS Pathways	2.0917 of 5 stars	3.5	3.0	1.3	0.8	0.6
OLMA Olema Pharmaceuticals	1.7764 of 5 stars	3.5	1.0	0.6	2.5	0.6
RANI Rani Therapeutics	1.4152 of 5 stars	3.5	1.0	0.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.11	Buy	$53.50	333.20% Upside
CMPS COMPASS Pathways	3.00	Buy	$18.83	292.36% Upside
OLMA Olema Pharmaceuticals	3.00	Buy	$24.50	497.56% Upside
RANI Rani Therapeutics	3.00	Buy	$7.33	1,343.57% Upside

Current Analyst Ratings Breakdown

Latest RANI, CMPS, OLMA, and ARCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00
5/16/2025	RANI Rani Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$14.00 ➝ $4.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/14/2025	OLMA Olema Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $18.00
5/14/2025	OLMA Olema Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $22.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00
5/13/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
4/28/2025	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$152.31M	2.20	N/A	N/A	$8.90 per share	1.39
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$2.26 per share	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$7.14 per share	N/A
RANI Rani Therapeutics	$1.03M	28.35	N/A	N/A	$0.06 per share	8.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	8/4/2025 (Estimated)
CMPS COMPASS Pathways	-$155.12M	-$1.99	N/A	N/A	N/A	N/A	-81.75%	-59.42%	7/30/2025 (Estimated)
OLMA Olema Pharmaceuticals	-$129.47M	-$2.01	N/A	N/A	N/A	N/A	-42.31%	-38.32%	8/5/2025 (Estimated)
RANI Rani Therapeutics	-$30.02M	-$0.99	N/A	N/A	N/A	N/A	-1,258.76%	-80.52%	8/5/2025 (Estimated)

Latest RANI, CMPS, OLMA, and ARCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	OLMA Olema Pharmaceuticals	-$0.49	-$0.36	+$0.13	-$0.36	N/A	N/A
5/13/2025	Q1 2025	RANI Rani Therapeutics	-$0.22	-$0.22	N/A	-$0.22	N/A	$0.20 million
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A
3/31/2025	Q4 2024	RANI Rani Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	$1.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	0.06	5.64	5.64
CMPS COMPASS Pathways	0.11	10.18	10.18
OLMA Olema Pharmaceuticals	N/A	15.22	15.22
RANI Rani Therapeutics	2.75	0.88	0.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
CMPS COMPASS Pathways	46.19%
OLMA Olema Pharmaceuticals	91.78%
RANI Rani Therapeutics	30.19%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	16.60%
CMPS COMPASS Pathways	3.93%
OLMA Olema Pharmaceuticals	16.36%
RANI Rani Therapeutics	50.42%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.62 million	Optionable
CMPS COMPASS Pathways	120	93.56 million	89.89 million	Optionable
OLMA Olema Pharmaceuticals	70	68.42 million	57.23 million	Optionable
RANI Rani Therapeutics	110	57.48 million	28.50 million	Optionable

RANI, CMPS, OLMA, and ARCT Headlines

Recent News About These Companies

Rani Therapeutics announces annual meeting results

May 30, 2025 | investing.com

Rani Therapeutics strikes deal to issue new warrants

May 21, 2025 | uk.investing.com

RANI: 1Q:25 Financial Results

May 20, 2025 | finance.yahoo.com

Rani Therapeutics Announces Research Agreement with Chugai

May 19, 2025 | globenewswire.com

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

May 13, 2025 | globenewswire.com

Rani Therapeutics Faces Nasdaq Compliance Challenge

May 6, 2025 | tipranks.com

Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)

April 23, 2025 | markets.businessinsider.com

Rani Therapeutics management to meet virtually with Lake Street

April 17, 2025 | markets.businessinsider.com

RANI: 2024 Financial Results

April 3, 2025 | finance.yahoo.com

Earnings call transcript: Rani Therapeutics sees stock drop despite narrowing losses in Q4 2024

April 2, 2025 | investing.com

Q4 2024 Rani Therapeutics Holdings Inc Earnings Call

April 1, 2025 | finance.yahoo.com

Rani Therapeutics reports Q4 EPS (27c), consensus (23c)

April 1, 2025 | markets.businessinsider.com

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2024 Earnings Call Transcript

April 1, 2025 | msn.com

Rani Therapeutics Reports 2024 Financial Results and Updates

March 31, 2025 | tipranks.com

Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript

March 31, 2025 | seekingalpha.com

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

March 31, 2025 | globenewswire.com

An Overview of Rani Therapeutics Hldgs's Earnings

March 28, 2025 | benzinga.com

Stifel Nicolaus Reaffirms Their Buy Rating on Rani Therapeutics Holdings (RANI)

March 28, 2025 | markets.businessinsider.com

Rani announces pharmacokinetic, pharmacodynamic data from RT-114 trial

March 27, 2025 | markets.businessinsider.com

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

March 26, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
By Nathan Reiff | June 9, 2025
View 3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup
By Gabriel Osorio-Mazilli | June 16, 2025
View Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup

RANI, CMPS, OLMA, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$12.35 +0.07 (+0.57%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$12.70 +0.35 (+2.80%)

As of 06/18/2025 07:59 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

COMPASS Pathways NASDAQ:CMPS

$4.80 +0.32 (+7.14%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$4.96 +0.17 (+3.44%)

As of 06/18/2025 07:52 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Olema Pharmaceuticals NASDAQ:OLMA

$4.10 +0.09 (+2.24%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$4.03 -0.07 (-1.80%)

As of 06/18/2025 05:51 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Rani Therapeutics NASDAQ:RANI

$0.51 -0.01 (-1.15%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$0.53 +0.03 (+4.92%)

As of 06/18/2025 07:51 PM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time